menu
    • menu
    [{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Praziquantel","moa":"Voltage-activated calcium channel beta 1 subunit | Voltage-activated calcium channel beta 2 subunit||Voltage-activated calcium channel beta 2 subunit | Voltage-activated calcium channel beta 1 subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Khartoum","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SUDAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Praziquantel","moa":"Voltage-activated calcium channel beta 1 subunit | Voltage-activated calcium channel beta 2 subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Khartoum","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Khartoum \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"University of Khartoum \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Regionshospital Nordjylland","sponsor":"Charite University, Berlin, Germany | Leiden University Medical Center | Nagasaki University | Ume\u00e5 University | Merck Group | Ministry of Health, Madagascar","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Praziquantel","moa":"Voltage-activated calcium channel beta 1 subunit | Voltage-activated calcium channel beta 2 subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Regionshospital Nordjylland","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Regionshospital Nordjylland \/ Charite University, Berlin, Germany | Leiden University Medical Center | Nagasaki University | Ume\u00e5 University | Merck Group | Ministry of Health, Madagascar","highestDevelopmentStatusID":"9","companyTruncated":"Regionshospital Nordjylland \/ Charite University, Berlin, Germany | Leiden University Medical Center | Nagasaki University | Ume\u00e5 University | Merck Group | Ministry of Health, Madagascar"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Praziquantel","moa":"Voltage-activated calcium channel beta 1 subunit | Voltage-activated calcium channel beta 2 subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Praziquantel","moa":"Voltage-activated calcium channel beta 1 subunit | Voltage-activated calcium channel beta 2 subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Praziquantel","moa":"Voltage-activated calcium channel beta 1 subunit | Voltage-activated calcium channel beta 2 subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Praziquantel

    Menu

    Praziquantel

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Regionshospital Nordjylland

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Regionshospital Nordjylland

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Charite University, Berlin, Germany | Leiden University Medical Center | Nagasaki University | Umeå University | Merck Group | Ministry of Health, Madagascar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study

                            Details : Praziquantel is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Schistosomiasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 03, 2019

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Charite University, Berlin, Germany | Leiden University Medical Center | Nagasaki University | Umeå University | Merck Group | Ministry of Health, Madagascar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Merck Group

                            Germany arrow
                            Florida Innovation
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            L-PZQ ODT in Schistosoma Infected Children

                            Details : L-PZQ (Praziquantel) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Schistosomiasis.

                            Product Name : L-PZQ

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 19, 2019

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Merck Group

                            Germany arrow
                            Florida Innovation
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Praziquantel Bioequivalence Study

                            Details : Cisticid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 19, 2018

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Merck Group

                            Germany arrow
                            Florida Innovation
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Manson...

                            Details : Biltricide (Praziquantel) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Schistosomiasis.

                            Product Name : Biltricide

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 20, 2016

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Merck Group

                            Germany arrow
                            Florida Innovation
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers

                            Details : Praziquantel is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 25, 2014

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University of Khartoum

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            University of Khartoum

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Schistosoma Haematobium Infections and Praziquantel

                            Details : Praziquantel is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Schistosomiasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 20, 2012

                            Lead Product(s) : Praziquantel

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth